Summary
Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects
- The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
AbbVie Inc
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed GmbH
Amgen Inc.
Arno Therapeutics, Inc.
Bellicum Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Faron Pharmaceuticals Oy
Gamida Cell Ltd.
Incyte Corporation
Merck & Co., Inc.
Merck KGaA
Mesoblast Limited
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc.
Molecular Templates Inc.
NantKwest, Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Philogen S.p.A.
Polyphor Ltd.
Rich Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Taiwan Liposome Company, Ltd.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Theravectys SA
TRACON Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview 9
Therapeutics Development 10
Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview 10
Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis 11
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Development by Companies 12
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Investigation by Universities/Institutes 15
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Development by Companies 19
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Investigation by Universities/Institutes 23
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development 24
4SC AG 24
AbbVie Inc 25
Acetylon Pharmaceuticals, Inc. 26
Actinium Pharmaceuticals, Inc. 27
ADC Therapeutics Sarl 28
Affimed GmbH 29
Amgen Inc. 30
Arno Therapeutics, Inc. 31
Bellicum Pharmaceuticals, Inc. 32
Bristol-Myers Squibb Company 33
Celgene Corporation 34
Cell Medica Limited 35
Cellular Biomedicine Group, Inc. 36
Constellation Pharmaceuticals, Inc. 37
Curis, Inc. 38
Faron Pharmaceuticals Oy 39
Gamida Cell Ltd. 40
Incyte Corporation 41
Merck & Co., Inc. 42
Merck KGaA 43
Mesoblast Limited 44
Millennium Pharmaceuticals Inc 45
Mirati Therapeutics Inc. 46
Molecular Templates Inc. 47
NantKwest, Inc. 48
Ono Pharmaceutical Co., Ltd. 49
Pfizer Inc. 50
Philogen S.p.A. 51
Polyphor Ltd. 52
Rich Pharmaceuticals, Inc. 53
Seattle Genetics, Inc. 54
Selvita S.A. 55
Sigma-Tau S.p.A. 56
Spectrum Pharmaceuticals, Inc. 57
Stemline Therapeutics, Inc. 58
Taiwan Liposome Company, Ltd. 59
Takeda Pharmaceutical Company Limited 60
TG Therapeutics, Inc. 61
Theravectys SA 62
TRACON Pharmaceuticals, Inc. 63
Trillium Therapeutics Inc. 64
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 72
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
(INCB-039110 + INCB-040093) - Drug Profile 82
ADCT-301 - Drug Profile 83
AFM-13 - Drug Profile 84
Alocrest - Drug Profile 88
AR-42 - Drug Profile 90
avelumab - Drug Profile 92
azacitidine - Drug Profile 97
balixafortide - Drug Profile 102
BC-8Y90 - Drug Profile 104
BMS-986016 - Drug Profile 105
BPX-501 - Drug Profile 107
brentuximab vedotin - Drug Profile 111
CBM-C30.1 - Drug Profile 135
Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile 136
Cellular Immunotherapy for Oncology - Drug Profile 137
Cellular Immunotherapy for Oncology - Drug Profile 138
Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 139
Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 140
Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile 141
Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer - Drug Profile 142
Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 143
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 144
Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile 145
CMD-003 - Drug Profile 146
CPI-0610 - Drug Profile 148
CUDC-907 - Drug Profile 149
Epstein-Barr virus vaccine - Drug Profile 154
Ferritarg - Drug Profile 155
FP-1305 - Drug Profile 156
haNK Program - Drug Profile 158
ibrutinib - Drug Profile 159
INCB-40093 - Drug Profile 184
Indimitecan - Drug Profile 185
Indotecan hydrochloride - Drug Profile 186
Iomab-B - Drug Profile 187
ipilimumab - Drug Profile 192
ixazomib citrate - Drug Profile 200
lirilumab - Drug Profile 209
MK-2206 - Drug Profile 213
mocetinostat - Drug Profile 216
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 221
MPC-CBE - Drug Profile 222
MT-17000 - Drug Profile 224
NiCord - Drug Profile 225
nivolumab - Drug Profile 228
NL-101 - Drug Profile 256
ONX-0801 - Drug Profile 258
pembrolizumab - Drug Profile 260
PF-06801591 - Drug Profile 291
PNK-007 - Drug Profile 292
procarbazine hydrochloride - Drug Profile 293
radretumab - Drug Profile 294
resminostat - Drug Profile 296
ricolinostat - Drug Profile 306
RP-323 - Drug Profile 314
ruxolitinib phosphate - Drug Profile 316
sapanisertib - Drug Profile 328
SEA-CD40 - Drug Profile 331
SEL-24B489 - Drug Profile 332
SL-101 - Drug Profile 333
SL-501 - Drug Profile 334
Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma - Drug Profile 335
temsirolimus - Drug Profile 336
TGR-1202 - Drug Profile 338
TRC-102 - Drug Profile 345
TTI-621 - Drug Profile 347
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 350
vinorelbine tartrate - Drug Profile 351
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects 352
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products 356
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones 357
Featured News & Press Releases 357
Appendix 370
Methodology 370
Coverage 370
Secondary Research 370
Primary Research 370
Expert Panel Validation 370
Contact Us 370
Disclaimer 371
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016 15
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2016 28
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by 4SC AG, H2 2016 29
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H2 2016 30
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 31
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 32
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics Sarl, H2 2016 33
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH , H2 2016 34
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Amgen Inc., H2 2016 35
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Arno Therapeutics, Inc., H2 2016 36
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 37
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016 38
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celgene Corporation, H2 2016 39
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cell Medica Limited, H2 2016 40
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 41
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 42
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis, Inc., H2 2016 43
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, H2 2016 44
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gamida Cell Ltd., H2 2016 45
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corporation, H2 2016 46
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co., Inc., H2 2016 47
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, H2 2016 48
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mesoblast Limited, H2 2016 49
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 50
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc., H2 2016 51
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Molecular Templates Inc., H2 2016 52
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NantKwest, Inc., H2 2016 53
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 54
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc., H2 2016 55
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Philogen S.p.A., H2 2016 56
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Polyphor Ltd., H2 2016 57
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals, Inc., H2 2016 58
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seattle Genetics, Inc., H2 2016 59
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Selvita S.A., H2 2016 60
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sigma-Tau S.p.A., H2 2016 61
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 62
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Stemline Therapeutics, Inc., H2 2016 63
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 64
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 65
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TG Therapeutics, Inc., H2 2016 66
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Theravectys SA, H2 2016 67
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 68
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Trillium Therapeutics Inc., H2 2016 69
Assessment by Monotherapy Products, H2 2016 70
Assessment by Combination Products, H2 2016 71
Number of Products by Stage and Target, H2 2016 73
Number of Products by Stage and Mechanism of Action, H2 2016 78
Number of Products by Stage and Route of Administration, H2 2016 83
Number of Products by Stage and Molecule Type, H2 2016 85
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2016 356
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..1), H2 2016 357
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..2), H2 2016 358
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..3), H2 2016 359
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H2 2016 360
List of Figures
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016 15
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 70
Number of Products by Top 10 Targets, H2 2016 72
Number of Products by Stage and Top 10 Targets, H2 2016 72
Number of Products by Top 10 Mechanism of Actions, H2 2016 77
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 77
Number of Products by Routes of Administration, H2 2016 82
Number of Products by Stage and Routes of Administration, H2 2016 82
Number of Products by Top 10 Molecule Types, H2 2016 84
Number of Products by Stage and Top 10 Molecule Types, H2 2016 84
